NewLink Genetics and Lumos Pharma to merge to develop LUM 201 under the name Lumos Pharma.

NewLink Genetics Corporation and Lumos Pharma, Inc., a private clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare diseases, announced that the companies have entered into a definitive merger agreement. Under the terms of the agreement, NewLink will issue Lumos Pharma stockholders NewLink common stock in exchange for their shares in Lumos such that Lumos Pharma stockholders will own approximately 50% of NewLink. Immediately following the closing of the merger, Lumos Pharma will become a wholly-owned subsidiary of NewLink, and NewLink will be renamed �Lumos Pharma, Inc.� and will trade on Nasdaq under the symbol �LUMO.The proposed merger would create a biopharmaceutical company focused initially on the development of Lumos Pharma�s lead candidate, LUM-201 (ibutamoren), a potential oral therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders